Molecular Imaging Market Size was valued at USD 8.47 billion in 2023 and is expected to reach USD 12.5 billion by 2032, growing at a CAGR of 4.5% over the forecast period 2024-2032.
The molecular imaging market is dominated by exponential growth due to rising chronic diseases, technological advancement, and high demand for early and accurate diagnosis. Based on the WHO report, cancer is one of the leading causes of death across the globe. In 2020, it caused about 9.6 million deaths. Further, the U.S. National Cancer Institute asserts that about 39.5% of men and women will be diagnosed with cancer at some points in their lifetime. This high prevalence of the disease influences the amount of allocation of government funds to enhance research on cancer and its diagnosis. For example, the U.S. National Institutes of Health allocated $6.9 billion to research for cancer during FY 2021. The European Commission’s Horizon Europe allocated €6.8 billion to health research and innovation from 2021-2027, a significant portion dedicated to cancer diagnosis and manipulation.
The demand for molecular imaging is accelerated by the increasing population globally, especially among the aging group. The U.N. suggests that by 2050 more than one out of every six people will be over 65 years, compared to one out of every 11 persons in 2019. Human brains degenerate with age, leading to more vulnerable health conditions. For example, the prevalence of Alzheimers disease is high among the aging group. Molecular imaging plays a significant impact on the detection of the diseases in the early stages of the reduction of the Amyloid protein in human brains. Lastly, technological advancements also accelerate the growth of the market. For instance, there are hybrid imaging devices and radiotracers to enhance molecular imaging. Moreover, the invention of artificial intelligence to analyze an image for certain structures within a few seconds accelerates the diagnosis process. The COVID-19 pandemic enhanced the growth of the market to improve diagnosis.
Market Dynamics
Drivers
Continuous innovations, such as hybrid imaging systems and molecular probes, have enhanced image quality and sensitivity, broadening the applications of molecular imaging.
The increasing incidence of conditions like cancer and cardiovascular diseases has escalated the demand for precise diagnostic tools, positioning molecular imaging as a vital component in early detection and personalized treatment planning.
The increasing prevalence of chronic diseases is one of the major factors driving the growth of the Molecular Imaging Market. Changing lifestyles, the growing proportion of elderly populations, and environmental factors, among others, are leading to a higher incidence of malignancies and chronic disorders, including cancers, cardiovascular diseases, and neurological disorders. Because these diseases necessitate very early and precise detection in order to treat them effectively, advanced diagnostic tools such as molecular imaging are in greater demand.
Cancer is one of the leading causes of death in the world there are 9.6 million estimated deaths according to the World Health Organization (WHO) and this number is expected to increase. The techniques such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) which plays an important role in early diagnosis of cancer and hence increasing chances of survival. Molecular imaging is a very important step for detecting cancer, because it aids in location, the position, size, and spread of the cancer. As regards cardiovascular diseases, the American Heart Association report estimates that nearly 18.6 million adults in the US had some type of coronary artery disease in 2020. Molecular imaging techniques, such as PET scans, are now being used more frequently to find heart conditions, helping provide more detailed information about the underlying mechanism of heart disease, such as atherosclerosis or inflammation, which has the potential to help inform treatment decisions.
Restraints
Significant capital investment, along with operational and maintenance expenses, can limit accessibility, especially in resource-constrained settings and smaller healthcare facilities.
Inadequate coverage for molecular imaging procedures and radiopharmaceuticals creates uncertainties for healthcare providers, hindering widespread adoption of these technologies.
A major factor that hinders the growth of the molecular imaging market is the cost of molecular imaging systems. Besides these advanced imaging technologies, they often have rather high capital costs not only in purchasing but also in maintaining and operating the equipment. Healthcare professionals need training to use these systems, which increases the cost. Moreover, molecular imaging involves the use of high-cost radiopharmaceuticals, and the price of each procedure is high. The exorbitant costs can restrict access to advanced diagnostic tools for healthcare providers, particularly in developing or resource-limited environments. While these technologies may carry certain advantages over a clinical imaging standpoint, hospitals and clinics may resort to set alternatives for imaging that are much less pricey, therefore, burying molecular imaging deeper in the ground. This accessibility problem also hinders patient access to these advanced diagnostic tests, which can prolong diagnosis and treatment for patients who would benefit from earlier and more precise disease detection such as cancers and neurological disorders.
By Modality
The molecular imaging market was dominated by the SPECT segment with a revenue share of 42% in 2023. The dominant responsibility of SPECT can be accredited to numerous factors such as the stamina of SPECT systems, their price for other modalities, and their appropriateness for a wide range of essential conditions. In cardiology, neurology, and oncological applications, SPECT imaging is particularly useful. SPECT myocardial perfusion imaging is one of the most significant diagnostic tools used in cardiovascular diagnosis with over 6 million studies performed annually in the United States. In 2020, there were 2.5 million SPECT procedures reimbursed through the U.S. Centers for Medicare & Medicaid Services (CMS) in the elderly population, suggesting relatively high utilization of this imaging modality. In addition, technological developments have further improved SPECT capability, as in the availability of cadmium zinc telluride (CZT) detectors to greatly enhance imaging efficiency with improved image quality in less time. The European Association of Nuclear Medicine (EANM) guidelines also helped to standardize SPECT imaging protocols, making them more reliable and reproducible in the daily clinical setting. SPECT systems tend to be more affordable to operate and can be applied to a wider range of clinical disciplines, thus propelling their ascendancy in market leadership among emerging economies.
By Application
Oncology was the largest application segment that held a share of 32.0% of the molecular imaging market in 2023. This is largely because of the importance of molecular imaging in the diagnosis, staging, treatment planning, and monitoring of cancer. The urgent need for effective diagnostics is underscored by the fact that according to the World Health Organization, almost 10 million people globally died from cancer in 2020. According to The National Cancer Institute, as of 2018, they estimated that approximately 1,735,350 new cancer cases were being diagnosed in the United States. Molecular imaging techniques, especially PET-CT scans, have become key tools in oncology. According to 2019 CMS claims data, more than 2 million PET-CT scans were performed for oncology indications in the Medicare population alone. Molecular imaging is increasingly utilized as molecular imaging recommendations in ESMO guidelines are becoming more widespread in several cancer types translating to the use of molecular imaging in cancer management in more healthcare systems. Additionally, the use of new radiotracers is further widening molecular imaging applications in oncology. An example includes the approval of 68Ga-PSMA-11 by the FDA for prostate cancer imaging in 2020, which represents an important step forward in precision diagnostics. With increasing focus on personalized therapy in cancer treatment, there has also been a concomitant increase in the need for more detailed characterization of tumors and monitoring of treatment response which molecular imaging can provide.
By End-use
The hospital segment accounted for about 48% share of the molecular imaging market in 2023. Several reasons account for this huge market share. Large academic and tertiary care centers, where people usually go for their heart care, have the financial resources and patient volumes to justify the cost of expensive molecular imaging equipment. The American Hospital Association has many hospitals across the U.S. and in 2021, there were 6,093 hospitals. Most of the hospitals provide advanced imaging services. In 2018 alone there were an estimated 130 million emergency department visits by the U.S. Centers for Disease Control and Prevention (CDC) and many of those cases may have benefited from advanced imaging. In addition, hospitals often serve a more diverse patient population and a broader range of clinical specialties, requiring access to a wider array of molecular imaging modalities. Several radiopharmaceuticals and imaging agents have been approved by the U.S. Food and Drug Administration (FDA) for hospital use to increase the repertoire diagnosis. Furthermore, hospitals are also frequently at the front line of clinical trials implementing molecular imaging techniques. For example, many of the studies incorporating advanced imaging technologies are conducted by the National Institutes of Health (NIH) Clinical Center. The COVID-19 pandemic has underscored the vital role of hospital-based advanced diagnostics that may expedite investments in molecular imaging technologies.
North America held the largest share of the molecular imaging market in 2023, accounting for a market with a revenue share of 43%. The dominance of the region can be explained by superior healthcare systems, high healthcare spending, and quick acceptance and adoption of innovative medical technologies. In 2020, U.S. healthcare expenditures were $4.1 trillion. This significant investment allowed advanced molecular imaging systems to become ubiquitous in healthcare facilities. In particular, the U.S. Food and Drug Administration (FDA) has also become very active in approving new molecular imaging agents and technologies to encourage innovation. For instance, in 2021, the FDA approved 68Ga-PSMA-11 as the first PSMA-targeted PET imaging agent for prostate cancer, expanding diagnostic capabilities in oncology.
The Asia-Pacific region will record the fastest CAGR in the molecular imaging market between 2024-2032. Rising expenditure on healthcare escalated awareness regarding early disease detection, and advancement in access to modern healthcare technologies in developing economies are the few factors accelerating the market growth. In particular, China has been able to significantly increase the spectrum of molecular imaging. The National Health Commission of China reported that the number of PET-CT scanners in service in the country numbered 9723 by the end of 2020, which was more than the previous year by 15.7%. Similarly, the Indian Council of Medical Research (ICMR) has highlighted the strengths of molecular imaging in cancer research, which is likely to upsurge market growth of molecular imaging in the region.
Recent developments
In June 2024, Positron Corporation confirmed the sale of its Attrius PET system that will be installed at the Centre in accordance with the Centre timeline's at Q4 in 2024. Positioned as the industrys only Truly 2D quantitative PET, the Attrius offers high-resolution imaging for nuclear cardiology with a dedicated PET scanner.
FUJIFILM India on February 4, 2023, unveiled the Prime open MRI, the APERTO Lucent, with Arietta 850 DeepInsight and Arietta 650 DeepInsight ultrasound models, and the FDX Visionary-DR bone density scanner.
Key Service Providers/Manufacturers
GE Healthcare (Discovery MI, PET/CT Scanner)
Siemens Healthineers (Biograph mMR, Somatom PET-CT Scanner)
Philips Healthcare (Allegra PET/MR, PET/CT Scanner)
Canon Medical Systems Corporation (Vantage Galan 3T, Aquilion CT)
Elekta AB (Unity MR-Linac, Elekta Synergy)
Medtronic (HIFU, Cryoablation)
Thermo Fisher Scientific (Tri-Carb, Femtosecond Laser Systems)
PerkinElmer (IVIS Spectrum, VICTOR Nivo)
Invivo (a part of Philips) (MRI Coil, PET/CT Scan)
Hitachi Medical Systems (PET Scanner, HITACHI AIRIS V)
Users of Services and Products
Johns Hopkins Medicine
Mayo Clinic
Cleveland Clinic
Memorial Sloan Kettering Cancer Center
MD Anderson Cancer Center
The Mayo Clinic
University of California, San Francisco (UCSF)
Stanford Health Care
Kaiser Permanente
Mount Sinai Health System
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | USD 8.47 Billion |
| Market Size by 2032 | USD 12.5 Billion |
| CAGR | CAGR of 4.5% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Modality (Molecular Ultrasound Imaging, Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), Nuclear Magnetic Resonance (NMR) Spectrometer, Other Modalities) • By Application (Cardiovascular, Neurology, Oncology, Respirator, Gastrointestinal) • By End-use (Hospitals, Diagnostic Imaging Centers, Research Institutes) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | GE Healthcare, Siemens Healthineers, Philips Healthcare, Canon Medical Systems Corporation, Elekta AB, Medtronic, Thermo Fisher Scientific, PerkinElmer, Invivo (a part of Philips), Hitachi Medical Systems. |
| Key Drivers | • Continuous innovations, such as hybrid imaging systems and molecular probes, have enhanced image quality and sensitivity, broadening the applications of molecular imaging. • The increasing incidence of conditions like cancer and cardiovascular diseases has escalated the demand for precise diagnostic tools, positioning molecular imaging as a vital component in early detection and personalized treatment planning. |
| Restraints | • Significant capital investment, along with operational and maintenance expenses, can limit accessibility, especially in resource-constrained settings and smaller healthcare facilities. |
Ans. The projected market size for the Molecular Imaging Market is USD 12.5 Billion by 2032.
Ans: The North American region dominated the Molecular Imaging Market in 2023.
Ans. The CAGR of the Molecular Imaging Market is 4.5% During the forecast period of 2024-2032.
Ans: The major key players in the market are GE Healthcare, Siemens Healthineers, Philips Healthcare, Canon Medical Systems Corporation, Elekta AB, Medtronic, Thermo Fisher Scientific, PerkinElmer, Invivo (a part of Philips), Hitachi Medical Systems, and others in the final report.
Ans:
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence of Target Diseases (2023)
5.2 Adoption Rates and Technological Advancements (2023)
5.3 Imaging Device Volume and Usage Trends (2020–2032)
5.4 Healthcare Expenditure on Molecular Imaging (2023)
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Molecular Imaging Market Segmentation, By Modality
7.1 Chapter Overview
7.2 Molecular Ultrasound Imaging
7.2.1 Molecular Ultrasound Imaging Market Trends Analysis (2020-2032)
7.2.2 Molecular Ultrasound Imaging Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Positron Emission Tomography (PET)
7.3.1 Positron Emission Tomography (PET) Market Trends Analysis (2020-2032)
7.3.2 Positron Emission Tomography (PET) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Single Photon Emission Computed Tomography (SPECT)
7.4.1 Single Photon Emission Computed Tomography (SPECT) Market Trends Analysis (2020-2032)
7.4.2 Single Photon Emission Computed Tomography (SPECT) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 Nuclear Magnetic Resonance (NMR) Spectrometer
7.5.1 Nuclear Magnetic Resonance (NMR) Spectrometer Market Trends Analysis (2020-2032)
7.5.2 Nuclear Magnetic Resonance (NMR) Spectrometer Market Size Estimates and Forecasts to 2032 (USD Billion)
7.6 Other Modalities
7.6.1 Other Modalities Market Trends Analysis (2020-2032)
7.6.2 Other Modalities Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Molecular Imaging Market Segmentation, By Application
8.1 Chapter Overview
8.2 Cardiovascular
8.2.1 Cardiovascular Market Trends Analysis (2020-2032)
8.2.2 Cardiovascular Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Neurology
8.3.1 Neurology Market Trends Analysis (2020-2032)
8.3.2 Neurology Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Oncology
8.4.1 Oncology Market Trends Analysis (2020-2032)
8.4.2 Oncology Market Size Estimates and Forecasts to 2032 (USD Billion)
8.5 Respirator
8.5.1 Respirator Market Trends Analysis (2020-2032)
8.5.2 Respirator Market Size Estimates and Forecasts to 2032 (USD Billion)
and Forecasts to 2032 (USD Billion)
8.6 Gastrointestinal
8.6.1 Gastrointestinal Market Trends Analysis (2020-2032)
8.6.2 Gastrointestinal Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Molecular Imaging Market Segmentation, By End-use
9.1 Chapter Overview
9.2 Hospitals
9.2.1 Hospitals Market Trends Analysis (2020-2032)
9.2.2 Hospitals Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Diagnostic Imaging Centers
9.3.1 Diagnostic Imaging Centers Market Trends Analysis (2020-2032)
9.3.2 Diagnostic Imaging Centers Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Research Institutes
9.4.1 Research Institutes Market Trends Analysis (2020-2032)
9.4.2 Research Institutes Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Molecular Imaging Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.2.3 North America Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.2.4 North America Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.2.5 North America Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.2.6.2 USA Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.2.6.3 USA Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.2.7.2 Canada Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.2.7.3 Canada Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.2.8.2 Mexico Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.2.8.3 Mexico Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.3 Europe
10.3.1 Eastern Europe
10.3.1.1 Trends Analysis
10.3.1.2 Eastern Europe Molecular Imaging Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.1.3 Eastern Europe Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.3.1.4 Eastern Europe Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.1.5 Eastern Europe Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.3.1.6 Poland
10.3.1.6.1 Poland Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.3.1.6.2 Poland Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.1.6.3 Poland Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.3.1.7 Romania
10.3.1.7.1 Romania Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.3.1.7.2 Romania Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.1.7.3 Romania Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.3.1.8 Hungary
10.3.1.8.1 Hungary Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.3.1.8.2 Hungary Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.1.8.3 Hungary Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.3.1.9 Turkey
10.3.1.9.1 Turkey Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.3.1.9.2 Turkey Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.1.9.3 Turkey Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.3.1.10 Rest of Eastern Europe
10.3.1.10.1 Rest of Eastern Europe Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.3.1.10.2 Rest of Eastern Europe Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.1.10.3 Rest of Eastern Europe Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.3.2 Western Europe
10.3.2.1 Trends Analysis
10.3.2.2 Western Europe Molecular Imaging Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.2.3 Western Europe Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.3.2.4 Western Europe Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.2.5 Western Europe Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.3.2.6 Germany
10.3.2.6.1 Germany Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.3.2.6.2 Germany Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.2.6.3 Germany Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.3.2.7 France
10.3.2.7.1 France Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.3.2.7.2 France Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.2.7.3 France Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.3.2.8 UK
10.3.2.8.1 UK Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.3.2.8.2 UK Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.2.8.3 UK Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.3.2.9 Italy
10.3.2.9.1 Italy Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.3.2.9.2 Italy Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.2.9.3 Italy Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.3.2.10 Spain
10.3.2.10.1 Spain Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.3.2.10.2 Spain Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.2.10.3 Spain Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.3.2.11 Netherlands
10.3.2.11.1 Netherlands Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.3.2.11.2 Netherlands Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.2.11.3 Netherlands Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.3.2.12 Switzerland
10.3.2.12.1 Switzerland Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.3.2.12.2 Switzerland Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.2.12.3 Switzerland Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.3.2.13 Austria
10.3.2.13.1 Austria Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.3.2.13.2 Austria Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.2.13.3 Austria Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.3.2.14 Rest of Western Europe
10.3.2.14.1 Rest of Western Europe Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.3.2.14.2 Rest of Western Europe Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.2.14.3 Rest of Western Europe Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific Molecular Imaging Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.4.3 Asia Pacific Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.4.4 Asia Pacific Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.4.5 Asia Pacific Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.4.6 China
10.4.6.1 China Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.4.6.2 China Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.4.6.3 China Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.4.7 India
10.4.7.1 India Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.4.7.2 India Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.4.7.3 India Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.4.8.2 Japan Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.4.8.3 Japan Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.4.9.2 South Korea Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.4.9.3 South Korea Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.4.10 Vietnam
10.4.10.1 Vietnam Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.4.10.2 Vietnam Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.4.10.3 Vietnam Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.4.11 Singapore
10.4.11.1 Singapore Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.4.11.2 Singapore Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.4.11.3 Singapore Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.4.12 Australia
10.4.12.1 Australia Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.4.12.2 Australia Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.4.12.3 Australia Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.4.13 Rest of Asia Pacific
10.4.13.1 Rest of Asia Pacific Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.4.13.2 Rest of Asia Pacific Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.4.13.3 Rest of Asia Pacific Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Middle East
10.5.1.1 Trends Analysis
10.5.1.2 Middle East Molecular Imaging Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.1.3 Middle East Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.5.1.4 Middle East Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.5.1.5 Middle East Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.5.1.6 UAE
10.5.1.6.1 UAE Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.5.1.6.2 UAE Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.5.1.6.3 UAE Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.5.1.7 Egypt
10.5.1.7.1 Egypt Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.5.1.7.2 Egypt Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.5.1.7.3 Egypt Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.5.1.8 Saudi Arabia
10.5.1.8.1 Saudi Arabia Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.5.1.8.2 Saudi Arabia Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.5.1.8.3 Saudi Arabia Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.5.1.9 Qatar
10.5.1.9.1 Qatar Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.5.1.9.2 Qatar Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.5.1.9.3 Qatar Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.5.1.10 Rest of Middle East
10.5.1.10.1 Rest of Middle East Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.5.1.10.2 Rest of Middle East Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.5.1.10.3 Rest of Middle East Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.5.2 Africa
10.5.2.1 Trends Analysis
10.5.2.2 Africa Molecular Imaging Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.2.3 Africa Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.5.2.4 Africa Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.5.2.5 Africa Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.5.2.6 South Africa
10.5.2.6.1 South Africa Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.5.2.6.2 South Africa Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.5.2.6.3 South Africa Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.5.2.7 Nigeria
10.5.2.7.1 Nigeria Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.5.2.7.2 Nigeria Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.5.2.7.3 Nigeria Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.5.2.8 Rest of Africa
10.5.2.8.1 Rest of Africa Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.5.2.8.2 Rest of Africa Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.5.2.8.3 Rest of Africa Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Molecular Imaging Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.6.3 Latin America Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.6.4 Latin America Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.6.5 Latin America Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.6.6.2 Brazil Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.6.6.3 Brazil Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.6.7.2 Argentina Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.6.7.3 Argentina Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.6.8 Colombia
10.6.8.1 Colombia Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.6.8.2 Colombia Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.6.8.3 Colombia Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America Molecular Imaging Market Estimates and Forecasts, By Modality (2020-2032) (USD Billion)
10.6.9.2 Rest of Latin America Molecular Imaging Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.6.9.3 Rest of Latin America Molecular Imaging Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
11. Company Profiles
11.1 GE Healthcare
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Products/ Services Offered
11.1.4 SWOT Analysis
11.2 Siemens Healthineers
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Products/ Services Offered
11.2.4 SWOT Analysis
11.3 Philips Healthcare
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Products/ Services Offered
11.3.4 SWOT Analysis
11.4 Canon Medical Systems Corporation
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Products/ Services Offered
11.4.4 SWOT Analysis
11.5 Elekta AB
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Products/ Services Offered
11.5.4 SWOT Analysis
11.6 Medtronic
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Products/ Services Offered
11.6.4 SWOT Analysis
11.7 Thermo Fisher Scientific
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Products/ Services Offered
11.7.4 SWOT Analysis
11.8 PerkinElmer
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Products/ Services Offered
11.8.4 SWOT Analysis
11.9 Invivo (a part of Philips)
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Products/ Services Offered
11.9.4 SWOT Analysis
11.10 Hitachi Medical Systems.
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Products/ Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments:
By Modality
Molecular Ultrasound Imaging
Positron Emission Tomography (PET)
Single Photon Emission Computed Tomography (SPECT)
Nuclear Magnetic Resonance (NMR) Spectrometer
Other Modalities
By Application
Cardiovascular
Neurology
Oncology
Respirator
Gastrointestinal
By End-use
Hospitals
Diagnostic Imaging Centers
Research Institutes
Request for Segment Customization as per your Business Requirement: Segment Customization Request
REGIONAL COVERAGE:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Product Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Product Matrix which gives a detailed comparison of product portfolio of each company
Geographic Analysis
Additional countries in any of the regions
Company Information
Detailed analysis and profiling of additional market players (Up to five)
The Retinal Surgery Market was valued at USD 2.46 billion in 2023 and is expected to reach USD 4.16 billion by 2032 and grow at a CAGR of 6.05% by 2024-2032
The Gas Chromatography Market Size was valued at USD 3.48 billion in 2023 and is expected to reach USD 5.47 billion by 2032 and grow at a CAGR of 5.16% over the forecast period 2024-2032.
The Amniotic Products Market size USD 0.84 Billion in 2023 and anticipated to grow USD 1.67 Billion by 2032, with compound annual growth rate 7.98% during the forecast period 2024-2032.
The Dental Bone Grafts and Substitutes Market Size was valued at USD 1.24 billion in 2023 and is expected to reach USD 2.42 billion by 2032 and grow at a CAGR of 7.72% over the forecast period 2024-2032.
The Assisted Reproductive Technology (ART) Market size was estimated at USD 28.33 billion in 2023 and is expected to reach USD 55.09 billion by 2032 with a growing CAGR of 7.68% during the forecast period of 2024-2032.
The Psoriatic Arthritis Treatment Market was valued at USD 11.08 billion in 2023 and is expected to reach USD 25.41 billion by 2032, growing at a CAGR of 9.70% from 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2025 All Rights Reserved by SNS Insider Pvt Ltd
